Onychomysosis - Chanpiyon Zong Pye https://en.wikipedia.org/wiki/Onychomycosis
onikomikoz (Onychomycosis) se yon enfeksyon chanpiyon nan klou a. Sentòm yo ka gen ladan dekolorasyon klou blan oswa jòn, epesman klou a, ak separasyon klou a ak kabann klou a. Zong pye oswa zong ka afekte, men li pi komen pou zong pye. Konplikasyon yo ka gen ladan selulitis (cellulitis) nan janm ki pi ba a. Yon kantite diferan kalite chanpiyon ka lakòz onikomikoz (Onychomycosis), ki gen ladan dèrmatofit. Faktè risk yo enkli pye atlèt, lòt maladi klou, ekspoze a yon moun ki gen kondisyon an, maladi vaskilè periferik, ak fonksyon iminitè pòv.

Medikaman antifonjik terbinafine pran nan bouch parèt pi efikas men terbinafine asosye ak efè segondè nan fwa.

onikomikoz (Onychomycosis) rive nan apeprè 10 pousan nan popilasyon adilt la, ak moun ki pi gran yo afekte pi souvan. Gason yo afekte pi souvan pase fi. onikomikoz (Onychomycosis) reprezante apeprè mwatye nan maladi klou. Sa vle di ke defòmasyon nan zong pye yo kapab tou soti nan kòz lòt pase onikomikoz (Onychomycosis).

○ Tretman - Medikaman OTC
Li difisil pou trete onychomycosis ak medikaman aktualite paske li difisil pou dwòg antre zong pye yo epè.
#Ketoconazole
#Clotrimazole
#Miconazole
#Terbinafine
#Butenafine [Lotrimin]
#Tolnaftate

○ Tretman
Se tretman alontèm anjeneral obligatwa jiskaske zong pye ki enfekte a konplètman retire deyò.
#Terbinafine (oral)
#Itraconazole
#Efinaconazole lacquer [Jublia]
#Ciclopirox lacquer
Plis enfomasyon ― Kreyòl ayisyen
References Onychomycosis: Current trends in diagnosis and treatment 24364524
Antifonjik sistemik yo se tretman ki pi efikas. Meta-analiz yo montre pousantaj gerizon mikotik jan sa a: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48% . Debridement klou koncomitan ogmante plis pousantaj gerizon. Terapi aktualite ak ciclopirox mwens efikas; li gen yon pousantaj echèk ki depase 60%.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
 Onychomycosis 28722883 
NIH
Onychomycosis (Onikomikoz) se yon enfeksyon chanpiyon ki afekte klou yo. Lè li koze pa dermatophytes, li rele tinea unguium. Onychomycosis (Onikomikoz) gen ladan enfeksyon ki te koze pa dèrmatofit, ledven, ak mwazi. Yon pwoblèm klou ki pa koze pa yon enfeksyon chanpiyon rele nail dystrophy. Malgre ke li ka afekte tou de zong ak zong pye, Onychomycosis (Onikomikoz) zong pye se pi komen. Atik sa a diskite sou divès aspè nan Onychomycosis (Onikomikoz) zong pye, tankou enpak li, kalite klinik, etap, dyagnostik, ak tretman. Pandan ke li pa menase lavi, Onychomycosis (Onikomikoz) ka mennen nan konplikasyon grav tankou selulit, sepsis, enfeksyon nan zo, domaj tisi, ak pèt klou.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
 Terbinafine 31424802 
NIH
Terbinafine se yon medikaman ki konbat enfeksyon chanpiyon lè li bloke squalène epoxidase. Li efikas kont anpil kalite fongis po epi li apwouve pou trete chanpiyon klou (onychomycosis) lè yo pran oralman. Pandan ke pifò efè segondè tankou tèt fè mal ak pwoblèm nan lestomak yo minè epi yo ale poukont yo, chanjman nan gou (dysgeusia) ka varye soti nan modere a grav, pafwa ki mennen nan pèdi pwa. Chanjman gou pèmanan yo ra men yo te rapòte.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
 Onychomycosis: An Updated Review 31738146 
NIH
Onychomycosis se yon enfeksyon chanpiyon ki afekte klou. Anviwon 90 % nan enfeksyon zong pye ak 75 % nan enfeksyon zong se koze pa fongis (Trichophyton mentagrophytes, Trichophyton rubrum). Sentòm yo enkli dekolorasyon klou, epesman, separasyon klou a soti nan kabann klou a. Tretman anjeneral enplike medikaman oral tankou terbinafine oswa itraconazole, epi tretman topik se yon opsyon pou ka modere.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.